#United States #New York #Levi & Korsinsky #Gossamer Bio #PROSERA Trial

Gossamer Bio Investor Alert: A Call for Action

Investors in Gossamer Bio, Inc. (NASDAQ: GOSS) are being urged to participate in a class action lawsuit due to significant allegations of securities fraud. The law firm Levi & Korsinsky has announced that investors who purchased Gossamer securities between June 16, 2025, and February 20, 2026, may be entitled to recover their losses. The impetus for the class action comes after alarming revelations about the company's Phase 3 clinical trial results for its drug PROSERA, which reportedly failed to meet its primary endpoint.

Overview of the Case

On February 23, 2026, Gossamer Bio’s stock price plummeted from $2.13 to $0.42 in a single trading day, reflecting a staggering loss of over 80% of shareholder value. This drastic decline was triggered by the negative topline results from the PROSERA trial, which revealed that critical endpoints were not achieved as anticipated. The class action aims to address the financial fallout faced by investors who purchased shares at inflated prices, believing in the company's misleading assurances of effective trial execution.

Allegations of Mismanagement in Clinical Trials

The complaint notes significant problems with Gossamer's handling of the clinical trial's execution. It is alleged that the company did not accurately represent the characteristics and treatment backgrounds of the patients enrolled in its Latin American sites. Reports suggest that a majority of the patients had already undergone extensive treatments, which diverges from the company's claims regarding the trial population's profile. Specific statistics highlighted in the allegations include:

• - 55% of PROSERA patients were on multiple background therapies, pointing to a heavily-treated demographic.
• - 61% of patients were receiving prostacyclin therapy at the baseline, indicating a more complex treatment history than Gossamer disclosed.

Such inconsistencies are deemed significant, as they could distort the trial outcomes and ultimately affect the drug's perceived efficacy. Investors were allegedly led to believe that the trial was being conducted under optimal conditions, whereas the situation on the ground contradicted those assurances.

The Financial Recovery Process

Those affected by these developments are encouraged to assert their rights and seek compensation through the class action. Interested parties can contact Levi & Korsinsky for a confidential consultation. Importantly, there is no cost to file a claim, as these lawsuits operate on a contingency fee basis, meaning that fees are only collected when a settlement is reached.

Who is Eligible?

To join the lawsuit, investors need to demonstrate that they purchased Gossamer Bio’s stock within the designated class period and incurred financial losses as a result. Notably, even investors who have sold their shares at a loss can still participate in the suit. This ensures that all affected investors have the opportunity to recover their investments regardless of their current holding status.

Steps to Take for Involved Investors

• - Gather Documentation: Collect all relevant records, including purchase dates, share quantities, and transactions that will support your claims.
• - Contact Levi & Korsinsky: Reach out to their team for an evaluation to determine your eligibility for seeking compensation.
• - Stay Informed: Keep up with updates regarding the case as it progresses through the legal system.

As Joseph E. Levi, Esq. indicated, “The complaint raises serious questions about whether investors received accurate information regarding the operational integrity of this pivotal clinical trial.” With investor interest and potential damages at stake, this lawsuit represents a significant forum for holding the company accountable. Don’t miss the opportunity to secure your rights as an aggrieved investor.

Contact Information:
For further inquiry, investors can reach Joseph E. Levi at Levi & Korsinsky at (212) 363-7500 or through email at [email protected].

• ---

Navigating a class action lawsuit may initially seem daunting, but participating can be a crucial step toward financial recovery. If you’ve faced losses due to Gossamer Bio's purported misrepresentations, consider taking action before the upcoming deadlines.